Summit Therapeutics Gets $62 Mln Contract From Biomedical Advanced Research and Development Authority

Summit Therapeutics (SMMT), a developer of therapies for Duchenne muscular dystrophy and C. difficile infection (CDI), said early Monday it got a $62 million contract from the U.S. government’s Department of Health and Human Services.

The order from the Department of Health’s Biomedical Advanced Research and Development Authority (BARDA) will support the clinical and regulatory development of ridinilazole to treat CDI, including the company’s planned phase 3 development program, it said in a statement.

The terms make Summit eligible for receiving from BARDA $32 million to fund, in part, obtaining regulatory approval for and commencing enrollment and dosing into two planned phase 3 clinical trials of ridinilazole.

The additional funding is linked to three independent option work segments, which may be accepted by BARDA after certain development and other milestones for ridinilazole have been met.

Leave a Comment